7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $186M | -$131M | 18.3% | -115.9% | -61.6% | -17.0% | -$71M | $292M | $217M |
| 2024 | $259M | -$145M | 41.8% | -90.9% | -44.5% | -14.4% | -$22M | $296M | $322M |
| 2023 | $289M | -$138M | 48.5% | -11.0% | -33.2% | -9.3% | $61M | $524M | $575M |
| 2022 | $883M | $491M | 80.9% | 65.0% | 90.0% | 21.5% | $519M | $527M | $632M |
| 2021 | $799M | $469M | 82.4% | 69.4% | 148.7% | 24.5% | $354M | $531M | — |
| 2020 | $284M | $89M | 72.0% | 42.2% | 100.5% | 7.0% | $127M | $535M | — |
| 2019 | $143M | -$4M | 53.3% | 16.8% | — | — | $7M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $51M | -$12M | 40.1% | -29.3% | -6.1% | -2.1% | $4M | $147M | $70M |
| Mar '26 | $66M | -$4M | 51.2% | -3.3% | -1.8% | -0.5% | $4M | $241M | $166M |
| Dec '25 | $50M | -$36M | 25.8% | -117.9% | -16.8% | -4.6% | -$25M | $292M | $217M |
| Sep '25 | $42M | -$26M | 13.6% | -98.6% | -10.4% | -3.0% | -$18M | $293M | $244M |
| Jun '25 | $47M | -$40M | 16.4% | -139.8% | -14.9% | -4.4% | -$13M | $294M | $270M |
| Mar '25 | $47M | -$30M | 16.5% | -104.9% | -10.0% | -3.1% | -$14M | $295M | $285M |
| Dec '24 | $57M | -$26M | 34.3% | -66.7% | -8.0% | -2.6% | -$20M | $296M | $322M |
| Sep '24 | $69M | -$97M | 46.7% | -239.9% | -28.1% | -7.6% | $5M | $522M | $578M |
| Jun '24 | $69M | -$10M | 44.4% | -19.4% | -2.3% | -0.7% | $8M | $523M | $573M |
| Mar '24 | $64M | -$12M | 40.3% | -29.4% | -2.9% | -0.8% | -$14M | $523M | $562M |
| Dec '23 | $74M | -$106M | 52.6% | -9.6% | -25.4% | -7.1% | -$9M | $524M | $575M |
| Sep '23 | $67M | -$6M | 45.1% | -23.1% | -1.2% | -0.3% | -$2M | $525M | $580M |
| Jun '23 | $69M | -$7M | 37.2% | -16.9% | -1.3% | -0.3% | -$6M | $526M | $580M |
| Mar '23 | $79M | -$67000 | 57.4% | 3.2% | -0.0% | -0.0% | $77M | $527M | — |
| Dec '22 | $205M | $38M | 74.0% | 53.4% | 6.9% | 1.6% | $93M | $527M | $632M |
| Sep '22 | $191M | $44M | 80.0% | 61.1% | 8.8% | 2.0% | $104M | $528M | — |
| Jun '22 | $243M | $71M | 84.6% | 74.4% | 15.6% | 3.3% | $163M | $529M | — |
| Mar '22 | $244M | $67M | 83.6% | 68.5% | 17.5% | 3.3% | $160M | $530M | — |
| Dec '21 | $228M | $56M | 82.9% | 67.6% | 17.7% | 2.9% | $53M | $531M | — |
| Sep '21 | $205M | $54M | 84.3% | 75.9% | 17.8% | 2.8% | $104M | $532M | — |
How the market has priced MRVI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Maravai Lifesciences Holdings, Inc.'s revenue has declined 8.1% per year. These are computed facts, not advice.
As of FY2025, Maravai Lifesciences Holdings, Inc. reported $292M of total debt against $217M of cash; operating income covered interest expense -8.0×.
In FY2025, gross margin was 18.3%, operating margin -115.9%, and net margin -70.4%.
As of Sep '26, Maravai Lifesciences Holdings, Inc. traded at a price-to-earnings ratio of about 2.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.